| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by LCS.
Page 7: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1801 | 0 | 0 | 942 1987 CLINICAL RHEUMATOLOGY 6(4):608-609 HAMZA M; HAMZAOUI K; AYED K; ELEUCH M; ZRIBI A THALIDOMIDE AND CELL-MEDIATED IMMUNITY IN BEHCETS-DISEASE | 0 | 2 |
| 1802 | 0 | 0 | 943 1987 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 112(9):365-365 LENZ W THALIDOMIDE-CAUSED BIRTH-DEFECTS | 0 | 0 |
| 1803 | 3 | 38 | 944 1987 EUROPEAN JOURNAL OF PEDIATRICS 146(1):63-67 SCHAFER KH; KRAMER M INFANTILE HYPERTROPHIC PYLORIC-STENOSIS AFTER PRENATAL EXPOSURE TO THALIDOMIDE | 0 | 0 |
| 1804 | 0 | 0 | 945 1987 EXPERIMENTAL HEMATOLOGY 15(5):476-476 HULLIN R; VOGELSANG GB; BRUNDRETTE R; COLVIN OM; SANTOS GW; HESS AD INTRACELLULAR BINDING-PROTEINS FOR THALIDOMIDE | 0 | 0 |
| 1805 | 0 | 0 | 946 1987 JAPANESE JOURNAL OF PSYCHIATRY AND NEUROLOGY 41(2):197-206 KANNO O ELECTROENCEPHALOGRAPHIC STUDY OF 137 PATIENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 1 |
| 1806 | 0 | 0 | 950 1987 TERATOLOGY 35(2):A73-A73 HALES BF; JAIN R SPECIES-DIFFERENCES IN THE EFFECTS OF DRUG-METABOLIZING-ENZYMES ON THE TERATOGENICITY OF THALIDOMIDE IN RAT EMBRYO CULTURES | 0 | 1 |
| 1807 | 0 | 0 | 951 1987 TERATOLOGY 36(1):A8-A9 DEIONGH RU; MCCREDIE J QUANTITATIVE NEUROPATHOLOGY OF THE PERIPHERAL-NERVES IN RABBIT THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1808 | 0 | 0 | 952 1987 TERATOLOGY 36(3):435-435 KIDA M A QUARTER CENTURY IN THE THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1809 | 0 | 2 | 956 1988 ARCHIV DER PHARMAZIE 321(9):577-577 EGER K; BOLEWSKI J; FOLKERS G; GUTBROD O; JALALIAN M; VERSPOHL E; LUPKE NP ALPHA-PHTHALIMIDOADIPINIMIDE - SYNTHESIS, TERATOGENIC PROPERTIES AND EFFECT ON THE CENTRAL NERVOUS-SYSTEM OF A HOMO-THALIDOMIDE | 0 | 0 |
| 1810 | 0 | 0 | 957 1988 ARCHIV DER PHARMAZIE 321(9):602-602 HESS HR; BLASCHKE G HYDROXYLATION, A STEP IN THALIDOMIDE METABOLIZATION | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1811 | 5 | 8 | 965 1988 BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 95(7):717-719 MAOURIS PG; HIRSCH PJ PREGNANCY IN WOMEN WITH THALIDOMIDE-INDUCED DISABILITIES - CASE-REPORT AND A QUESTIONNAIRE STUDY | 0 | 4 |
| 1812 | 0 | 0 | 976 1988 LEPROSY REVIEW 59(2):184-185 BOURDILLON C THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM (ENL) | 0 | 0 |
| 1813 | 0 | 0 | 977 1988 NATURE 336(6195):101-101 EWING T THALIDOMIDE SCIENTIST GUILTY OF FRAUD SAYS COMMITTEE | 0 | 2 |
| 1814 | 0 | 0 | 978 1988 TERATOLOGY 38(2):199-199 MCBRIDE WG; CATALANO A; DUGUID P; HICKS L THE EFFECT OF THALIDOMIDE ADMINISTRATION ON GABA AND OTHER AMINO-ACIDS IN THE MARMOSET EMBRYO | 0 | 0 |
| 1815 | 1 | 1 | 986 1989 ANAESTHESIA 44(1):69-69 GRAYLING GW; YOUNG PN ANESTHESIA AND THALIDOMIDE-RELATED ABNORMALITIES | 0 | 0 |
| 1816 | 6 | 11 | 988 1989 BIOCHEMICAL SOCIETY TRANSACTIONS 17(1):114-115 LYNE C; GOWER DB RADIAL THIN-LAYER CHROMATOGRAPHIC AUTORADIOGRAPHIC SCANS OF STEROID-METABOLISM IN THE PRESENCE OF THALIDOMIDE | 0 | 1 |
| 1817 | 3 | 6 | 991 1989 BRITISH MEDICAL JOURNAL 298(6665):6-6 CHAMBERLAIN G THE OBSTETRIC PROBLEMS OF THE THALIDOMIDE CHILDREN | 0 | 0 |
| 1818 | 7 | 27 | 1005 1990 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 40-1(1):32-36 BUCH HP; OMLOR G; KNABE J STEREOSELECTIVE DIFFERENCES OF THE CNS-DEPRESSANT ACTIVITY IN A HOMOLOGOUS SERIES OF 3-ALKYL-THALIDOMIDE ANALOGS | 0 | 5 |
| 1819 | 0 | 16 | 1008 1990 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 115(25):977-979 BROCHELER J; HALFMANN R ANTERIOR SACRAL MENINGOCELE ASSOCIATED WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1820 | 2 | 7 | 1009 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(5):482-483 JEW LJ; MIDDLETON RK THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1821 | 0 | 0 | 1012 1990 GAZETTE MEDICALE 97(3):26-27 BELAICH S USE OF THALIDOMIDE IN DERMATOLOGY | 0 | 0 |
| 1822 | 0 | 9 | 1013 1990 GEBURTSHILFE UND FRAUENHEILKUNDE 50(11):899-900 SCHAEFER C; SPIELMANN H COCAINE AND PREGNANCY - SHADES OF THE THALIDOMIDE TRAGEDY | 0 | 0 |
| 1823 | 2 | 7 | 1024 1990 MEDICAL JOURNAL OF AUSTRALIA 152(3):148-149 BROWN MA; FARRELL C; NEWTON P; CHILD RP THALIDOMIDE, PREGNANCY AND RENAL-FAILURE | 0 | 0 |
| 1824 | 0 | 2 | 1027 1990 PRESSE MEDICALE 19(15):722-722 LIVROZET JM; FRANC C; GRANIER JL; BRETON P; TOURAINE JL THALIDOMIDE TREATMENT OF CHOICE OF APHTHAE IN HIV-INFECTION - REPLY | 0 | 0 |
| 1825 | 4 | 12 | 1031 1990 TERATOLOGY 41(2):241-242 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1826 | 0 | 16 | 1034 1990 TOXICOLOGY LETTERS 50(2-3):309-318 SHIOTA K; UWABE C; YAMAMOTO M; ARISHIMA K SUSCEPTIBILITY TO CYCLOPHOSPHAMIDE AND THALIDOMIDE OF FETAL-RAT LIMB BUDS GRAFTED IN ATHYMIC (NUDE) MICE | 0 | 0 |
| 1827 | 5 | 10 | 1040 1991 BRITISH MEDICAL JOURNAL 303(6809):1062-1063 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 0 | 0 |
| 1828 | 0 | 0 | 1043 1991 EXPERIMENTAL HEMATOLOGY 19(6):553-553 VOGELSANG GB; BUJNOVSZKY C; BOUCHER C; LEONG K; JALALIAN M; HESS A; SANTOS GW INVITRO IMMUNOLOGICAL EFFECTS OF THALIDOMIDE | 0 | 0 |
| 1829 | 1 | 7 | 1050 1991 NEURO-OPHTHALMOLOGY 11(1):29-32 HUYGEN PLM; VANRIJN PM; VERHAGEN WIM; CREMERS CWRJ; THEUNISSEN EJJM SUBCORTICAL OPTOKINETIC RESPONSE IN A CASE OF THALIDOMIDE FETOPATHY | 0 | 1 |
| 1830 | 1 | 6 | 1053 1992 ANNALES DE MEDECINE INTERNE 143(7):479-480 LOUZIR B; OTHMANI S; GRITLI N; BEJI M; ZIDI B; MSADDEK F; BOUSSEMA E; BAHRI M ACUTE MYELOID-LEUKEMIA IN A BEHCETS-DISEASE PATIENT UNDER LONG-TERM THALIDOMIDE TREATMENT | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1831 | 2 | 2 | 1068 1992 LANCET 339(8805):1362-1362 HIGGINS SP; BRADBEER CS THALIDOMIDE - A RESTRICTED ROLE | 0 | 0 |
| 1832 | 2 | 9 | 1074 1992 TERATOLOGY 46(5):411-413 LIPSON AH THALIDOMIDE RETROSPECTIVE - WHAT DID THE CLINICAL TERATOLOGIST LEARN | 0 | 3 |
| 1833 | 6 | 37 | 1080 1992 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 47(1-2):155-169 KOCHERBECKER U; KOCHER W; OCKENFELS H EMBRYOTOXIC INTERACTIONS BETWEEN A HYDROLYSIS PRODUCT OF THALIDOMIDE AND THE SURFACTANT TWEEN 20 IN MICE | 0 | 0 |
| 1834 | 0 | 0 | 1081 1993 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 206:216-MEDI HE WX; ENGSTROM L; WALKER S; VOGELSANG G; LEONG KW SYNTHESIS OF THALIDOMIDE ANALOGS AND THEIR BIOLOGICAL POTENTIAL FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 1835 | 0 | 1 | 1083 1993 AMERICAN SCIENTIST 81(5):425-426 HOFFMAN M A 2ND CHANCE FOR THALIDOMIDE | 0 | 0 |
| 1836 | 0 | 0 | 1088 1993 BLOOD 82(10):A421-A421 VOGELSANG GB; COLVIN OM; ALTOMONTE V; PIANTADOSI S; HESS AD; SANTOS GW EFFECT OF THALIDOMIDE DOSE AND PLASMA-LEVEL ON PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 1837 | 0 | 0 | 1091 1993 BRITISH MEDICAL JOURNAL 307(6901):404-404 JOHN D DOCTOR WHO FOUND THALIDOMIDE DANGERS IS STRUCK OFF | 0 | 0 |
| 1838 | 0 | 1 | 1093 1993 CHEMICAL & ENGINEERING NEWS 71(28):5-5 BAUM R THALIDOMIDE BLOCKS VIRUS THAT CAUSES AIDS | 0 | 0 |
| 1839 | 0 | 1 | 1097 1993 GASTROENTEROLOGY 104(4):A683-A683 COHEN LB; PEAREN S; IAZZETTA J THALIDOMIDE FOR INFLAMMATORY BOWEL-DISEASE - A PRELIMINARY-REPORT | 0 | 0 |
| 1840 | 8 | 15 | 1098 1993 GASTROENTEROLOGY 105(3):956-956 RHOTON AJ ROLE FOR THALIDOMIDE IN PRIMARY BILIARY-CIRRHOSIS TREATMENT | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1841 | 0 | 0 | 1099 1993 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34(4):1479-1479 YAN GC; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 0 | 0 |
| 1842 | 0 | 0 | 1102 1993 JOURNAL OF INVESTIGATIVE DERMATOLOGY 100(4):492-492 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 0 | 0 |
| 1843 | 8 | 10 | 1104 1993 MEDICINA CLINICA 100(14):557-557 GARCIAALBEA E; CABRERA F; TEJEIRO J; JIMENEZJIMENEZ FJ MIGRAINE AND THALIDOMIDE | 0 | 0 |
| 1844 | 3 | 10 | 1105 1993 MEDICINA CLINICA 101(4):158-158 PIZARRO A; PINILLA J; GARCIATOBARUELA A THERAPY WITH THALIDOMIDE AND TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION | 0 | 1 |
| 1845 | 0 | 0 | 1107 1993 NEW SCIENTIST 137(1862):6-6 DAYTON L THALIDOMIDE HERO FOUND GUILTY OF SCIENTIFIC FRAUD | 0 | 0 |
| 1846 | 1 | 9 | 1109 1993 PHARMAZIE 48(2):147-148 HOFENEDER M; KREBS G; SUTTER B; KOCH HP ACUTE TOXICITY OF THALIDOMIDE, TAGLUTIMIDE AND SUPIDIMIDE IN THE YEAST-TEST | 0 | 2 |
| 1847 | 7 | 34 | 1113 1993 SPECTROSCOPY LETTERS 26(4):597-619 ROTHCHILD R; SANDERS K; VENKATASUBBAN KS NMR-STUDIES OF DRUGS - USE OF LANTHANIDE SHIFT-REAGENTS IN POLAR-SOLVENT WITH THALIDOMIDE | 0 | 6 |
| 1848 | 0 | 0 | 1122 1994 BLOOD 84(10):A335-A335 PARKER PM; NADEMANEE A; ODONNELL MR; SNYDER DS; STEIN A; SMITH E; MOLINA A; STEPAN DE; CHAO N; NILAND JC; BLUME KG; FORMAN SJ NEUTROPENIA IS A COMPLICATION OF THALIDOMIDE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 1849 | 0 | 0 | 1134 1994 CHEMISTRY IN BRITAIN 30(4):280-280 CAREY J THALIDOMIDE DEBATE - REPLY | 0 | 0 |
| 1850 | 0 | 0 | 1135 1994 CHEMISTRY IN BRITAIN 30(4):280-280 HUNT JR THALIDOMIDE DEBATE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1851 | 0 | 0 | 1137 1994 CLINICAL RESEARCH 42(2):A142-A142 RIFKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM INDUCTION OF TH2, AND INHIBITION OF TH1, LYMPHOCYTE-RESPONSES BY THALIDOMIDE | 0 | 0 |
| 1852 | 13 | 24 | 1141 1994 FOLIA BIOLOGICA 40(4):161-171 BILA V; KREN V EVIDENCE FOR TERATOGENICITY OF THALIDOMIDE USING CONGENIC AND RECOMBINANT INBRED RAT STRAINS | 0 | 10 |
| 1853 | 0 | 0 | 1143 1994 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35(4):1996-1996 DAMATO RJ; LOUGHMAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 0 | 0 |
| 1854 | 4 | 13 | 1144 1994 JOURNAL OF CHEMICAL CRYSTALLOGRAPHY 24(1):95-99 CAIRA MR; BOTHA SA; FLANAGAN DR POLYMORPHISM OF N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE (THALIDOMIDE) - STRUCTURAL CHARACTERIZATION OF A 2ND MONOCLINIC RACEMIC MODIFICATION | 0 | 2 |
| 1855 | 0 | 0 | 1157 1994 PANMINERVA MEDICA 36(1):44-47 VOSGERAU JCB ATYPICAL HERPES SIMPLE - A SIGN OF TOXOPLASMOSIS ACTIVITY IN AIDS PATIENTS AND THE USE OF THALIDOMIDE | 0 | 1 |
| 1856 | 0 | 0 | 1161 1994 REVISTA BRASILEIRA DE GENETICA 17(4):449-464 SALDANHA PH THE THALIDOMIDE-TRAGEDY AND THE BIRTH OF EXPERIMENTAL TERATOLOGY | 0 | 0 |
| 1857 | 0 | 0 | 1173 1995 ARTHRITIS AND RHEUMATISM 38(9):769-769 SCOVILLE CD OPEN TRIAL OF THALIDOMIDE IN THE TREATMENT OF RHEUMATOID-ARTHRITIS | 0 | 0 |
| 1858 | 0 | 0 | 1176 1995 BLOOD 86(10):1577-1577 Browne PV; Wagner J; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Enright H Response to thalidomide therapy in patients with refractory chronic graft-versus-host disease. | 0 | 0 |
| 1859 | 0 | 0 | 1180 1995 CHEMISTRY IN BRITAIN 31(10):760-760 [Anon] THALIDOMIDE REVIVAL | 0 | 0 |
| 1860 | 5 | 6 | 1182 1995 CLINICAL AND EXPERIMENTAL DERMATOLOGY 20(1):85-85 MISERY L; PEGUETNAVARRO J; THIVOLET J; FAURE M; SCHMITT D; CLAUDY AL THALIDOMIDE DOES NOT AFFECT IN-VITRO MIXED SKIN CELL LYMPHOCYTE REACTIONS | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1861 | 0 | 0 | 1189 1995 ENVIRONMENTAL HEALTH PERSPECTIVES 103(2):132-132 [Anon] RETHINKING THALIDOMIDE | 0 | 0 |
| 1862 | 0 | 0 | 1190 1995 EUROPEAN CHEMICAL NEWS 63(1667):8-8 [Anon] GUINNESS TOPS UP THALIDOMIDE FUND | 0 | 0 |
| 1863 | 0 | 0 | 1200 1995 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 36(4):S225-S225 DAMATO RJ; KENYON BM FURTHER-STUDIES EXAMINING THE EFFECTS OF THALIDOMIDE ON ANGIOGENESIS | 0 | 0 |
| 1864 | 0 | 0 | 1208 1995 KIDNEY INTERNATIONAL 47(2):672-672 RIFLKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM THALIDOMIDE AS TREATMENT FOR REFRACTORY SYSTEMIC VASCULITIS - POSSIBLE MECHANISM OF ACTION | 0 | 0 |
| 1865 | 0 | 0 | 1213 1995 MOLECULAR BIOLOGY OF THE CELL 6:1195-1195 DESESSO JM; HARRIS SB; SCIALLI AR; GOERINGER GC EARLY MICROSCOPIC OBSERVATIONS OF THALIDOMIDE-INDUCED LIMB DEFECTS IN NEW-ZEALAND WHITE-RABBITS | 0 | 0 |
| 1866 | 5 | 5 | 1215 1995 MOLECULAR MEDICINE TODAY 1(5):210-210 STEWART A IS THALIDOMIDE A MUTAGEN | 0 | 0 |
| 1867 | 1 | 1 | 1219 1995 POSTGRADUATE MEDICAL JOURNAL 71(832):123-123 JUDGE MR; KOBZABLACK A; HAWK JLM GUIDELINES FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 0 | 0 |
| 1868 | 2 | 3 | 1220 1995 PRESSE MEDICALE 24(1):40-40 COUDERC LJ; MATHEZ D; LEIBOWITCH J; AUTRAN B; CAUBARRERE I PROLONGED THALIDOMIDE TREATMENT IN AN HIV-INFECTED PATIENT | 0 | 1 |
| 1869 | 0 | 0 | 1221 1995 SEARCH 26(10):290-290 WESTMORE A HEREDITY OF THALIDOMIDE DEFORMITY DISPUTED | 0 | 0 |
| 1870 | 0 | 0 | 1223 1996 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 212:140-MEDI Niwayama S; Turk B; Liu J Potent inhibition of tumor necrosis factor-alpha by tetrafluoro-thalidomide and tetrafluorophthalimides | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1871 | 0 | 0 | 1224 1996 AIDS 10:P60-P60 FeregrinoGoyos M; GomezCaro WH; AlvaradoDiez R; Yieyra MPM; TorrasGiner V Thalidomide and ketoprofen reduce the incidence of adverse events of interleukin 2 and enhance the antiviral activity of CD8 in HIV/AIDS patients. | 0 | 0 |
| 1872 | 0 | 0 | 1225 1996 AIDS 10:P102-P102 MacRedmond R; Keating S; Armstrong S; Ryan M; Mulcahy FM The use of oral thalidomide in the treatment of oesophageal ulceration in AIDS. | 0 | 0 |
| 1873 | 0 | 0 | 1227 1996 AIDS PATIENT CARE AND STDS 10(1):51-51 [Anon] Thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 1874 | 0 | 0 | 1228 1996 AIDS PATIENT CARE AND STDS 10(4):263-263 [Anon] Thalidomide trial for diarrhea | 0 | 0 |
| 1875 | 0 | 0 | 1229 1996 AMERICAN JOURNAL OF EPIDEMIOLOGY 143(11):6-6 Yang Q; Khoury MJ; James LM; Olney RS; Paulozzi LJ The return of thalidomide? Are birth defects surveillance systems ready? | 0 | 1 |
| 1876 | 1 | 2 | 1239 1996 ARCHIVES OF DISEASE IN CHILDHOOD 75(1):90-90 Harry TC Thalidomide treatment of mucosal ulcerations in HIV infection | 0 | 0 |
| 1877 | 0 | 0 | 1241 1996 ARTHRITIS AND RHEUMATISM 39(9):1352-1352 Stevens RJ; Andujar C; Edwards C; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. | 0 | 1 |
| 1878 | 0 | 0 | 1242 1996 ARTHRITIS AND RHEUMATISM 39(9):1353-1353 Sato EI; Assis LSS; Furtado R Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus (SLE) | 0 | 0 |
| 1879 | 0 | 0 | 1247 1996 BLOOD 88(10):2423-2423 Flowers MED; Tapscott SJ; Emerson J; Emerson MV; Reagan T; Taylor L; Ajer T; Siadak M; Sanders J; Zwingenberger K; Willsmann K; Appelbaum F; Sullivan KM Incidence of peripheral neuropathy (PN) prior to thalidomide treatment for chronic graft-versus-host disease (GVHD). | 0 | 0 |
| 1880 | 0 | 0 | 1248 1996 BLOOD 88(10):2424-2424 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Middleton G; Eisen T; Singhal S Thalidomide for acute or chronic graft-versus-host disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1881 | 1 | 5 | 1259 1996 ENDOSCOPY 28(5):471-472 Louvel D; Musso S; Metivier S; Croizet O; Rouquet RM; Massip P; Escourrou J; Frexinos J Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: Efficacy of thalidomide treatment | 0 | 1 |
| 1882 | 0 | 0 | 1262 1996 FASEB JOURNAL 10(6):303-303 Shannon EJ; Sandoval F; Krahenbuhl J Hydrolysis of thalidomide abrogates its ability to enhance IL-2 or to suppress TNF-alpha. | 0 | 0 |
| 1883 | 9 | 14 | 1263 1996 GASTROINTESTINAL ENDOSCOPY 44(6):729-731 Bellomo A; SchorrLesnick B Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV | 0 | 1 |
| 1884 | 0 | 0 | 1265 1996 IMMUNOLOGY 89:ORI27-ORI27 Marriott JB; Cookson S; Westby M; Guckian M; Dalgleish AG The effect of a thalidomide analogue on TNF-alpha/cytokine production in vitro | 0 | 0 |
| 1885 | 0 | 0 | 1266 1996 IMMUNOLOGY 89:E51-E51 Guckian M; Marriott JB; Cookson S; Westby M; Dalgleish G Thalidomide analog 3052 reduces NK activity and PHA-induced proliferation in vitro. | 0 | 0 |
| 1886 | 0 | 0 | 1272 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):546-546 Ozaki S; Yamana T; Kita M; Honda Y Effect of thalidomide on experimental choroidal neovascularization in pigmented rats | 0 | 0 |
| 1887 | 0 | 0 | 1273 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):572-572 Tsujikawa M; Saito Y; Tatebayashi M; Tano Y The inhibitory effect of thalidomide for experimental preretinal neovascularization by laser-induced venous occlusion in rats. | 0 | 0 |
| 1888 | 0 | 0 | 1274 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):3032-3032 Lansing MB; Dixit S; Glaser BM The effect of systemic thalidomide and amiloride on neovascularization in the rabbit corneal micropocket essay | 0 | 0 |
| 1889 | 0 | 0 | 1275 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):4015-4015 Zhang EP; Pleyer U; Hoffmann F; Hartmann C Effect of thalidomide on experimental keratoplasty | 0 | 0 |
| 1890 | 0 | 0 | 1284 1996 LANCET 348(9038):1370-1370 Barnett AA FDA encourages firms to test thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1891 | 0 | 0 | 1288 1996 NEUROLOGY 46(2):3015-3015 Openshaw H; Slatkin NE; Parker P Thalidomide neuropathy in bone marrow transplantation | 0 | 0 |
| 1892 | 0 | 0 | 1289 1996 NEUROLOGY 46(2):27003-27003 Chaudhry V; Cornblath D; Corse A; Freimer M; SimmonsOBrien E; Vogelsang G Thalidomide-induced neuropathy: Clinical and electrophysiological features | 0 | 0 |
| 1893 | 0 | 0 | 1290 1996 NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 22(5):456-456 Chakrabarty A; Bridges LR Cerebral malformation in a patient with thalidomide related phocomelia | 0 | 0 |
| 1894 | 2 | 7 | 1295 1996 REVISTA CLINICA ESPANOLA 196(4):270-271 Tercedor J; delaTorre ML; Rodenas JM Disseminated xanthoma with insipid diabetes: Therapeutic failure of thalidomide | 0 | 0 |
| 1895 | 0 | 6 | 1296 1996 SLEEP 19(2):116-116 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, immune modulation and narcolepsy | 0 | 2 |
| 1896 | 9 | 51 | 1297 1996 TERATOLOGY 54(3):126-134 Smith DM; Torres RD; Stephens TD Mesonephros has a role in limb development and is related to thalidomide embryopathy | 0 | 5 |
| 1897 | 0 | 0 | 1299 1997 AIDS PATIENT CARE AND STDS 11(4):292-292 [Anon] Limited course of thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 1898 | 0 | 0 | 1300 1997 AIDS PATIENT CARE AND STDS 11(4):292-293 [Anon] Clinical sites initiated for thalidomide aphthous ulcer study | 0 | 0 |
| 1899 | 0 | 0 | 1301 1997 AIDS PATIENT CARE AND STDS 11(4):296-296 [Anon] Positive results reported for thalidomide in AIDS wasting | 0 | 0 |
| 1900 | 0 | 1 | 1307 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(13):1485-1486 [Anon] Thalidomide heals HIV-related oral ulcers, but caution is required | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1901 | 0 | 0 | 1313 1997 ARTHRITIS AND RHEUMATISM 40(9):210-210 Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Randomised and placebo controlled trial of two different doses of thalidomide in Behcet's syndrome | 0 | 0 |
| 1902 | 0 | 0 | 1315 1997 BLOOD 90(10):1673-1673 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. | 0 | 0 |
| 1903 | 0 | 0 | 1316 1997 BLOOD 90(10):4423-4423 Mehta P; Gian VG; Smith SP; Beltz SE; Wingard JR Thalidomide is not effective for acute graft-versus-host disease. | 0 | 0 |
| 1904 | 2 | 5 | 1317 1997 BONE MARROW TRANSPLANTATION 19(1):95-96 Chen F; Tsang K; Liang R Thalidomide-responsive chronic pulmonary GVHD | 0 | 0 |
| 1905 | 0 | 0 | 1321 1997 CHEMISTRY & INDUSTRY (18):714-714 [Anon] Thalidomide for US | 0 | 0 |
| 1906 | 4 | 5 | 1327 1997 CLINICAL CHEMISTRY 43(6):1095-1096 Lyon AW; Raisys VA Handling of blood samples for determination of thalidomide - Respond | 0 | 0 |
| 1907 | 0 | 0 | 1330 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PI44-PI44 OToole EA; Nasca MR; Palicharla P; West DP; Woodley DT Thalidomide increases keratinocyte proliferation and chemokine secretion in vitro | 0 | 0 |
| 1908 | 0 | 0 | 1331 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PIV89-PIV89 Donahue SR; Collins JM; Flockhart DA; Abernethy DR; Trapnell CB Thalidomide pharmacokinetics do not change with chronic administration | 0 | 0 |
| 1909 | 0 | 0 | 1334 1997 DRUG NEWS & PERSPECTIVES 10(8):506-506 [Anon] Celgene's thalidomide approvable for ENL | 0 | 0 |
| 1910 | 0 | 0 | 1335 1997 EUROPEAN CHEMICAL NEWS 68(1780):51-51 [Anon] Celgene - FDA approves thalidomide's use against ENL | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1911 | 0 | 0 | 1337 1997 FORTUNE 136(6):36-& McLean B Thalidomide .2. | 0 | 0 |
| 1912 | 0 | 0 | 1346 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1240-1240 Lesk MR; Ponomarenko S; Filion B; Burnier M Effect of oral thalidomide on prolongation of rabbit sclerostomy function. | 0 | 0 |
| 1913 | 0 | 2 | 1347 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1680-1680 Joussen AM; Kruse FE; Becker M; Rohrschneider K; Volcker HE Thalidomide inhibits angiogenesis induced by vascular endothelial growth factor | 0 | 0 |
| 1914 | 0 | 0 | 1348 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):4467-4467 DAmato RJ; Verheul HMW; Panigrahy D; Yuan J Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs) | 0 | 0 |
| 1915 | 0 | 0 | 1349 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):5409-5409 Baatz H; Tonnessen B; Pleyer U; Hartmann C Thalidomide inhibits leukocyte-endothelium-interaction in endotoxin-induced uveitis | 0 | 0 |
| 1916 | 0 | 0 | 1350 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
| 1917 | 0 | 0 | 1355 1997 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 99(1):679-679 James DE; Jaffarian A; Biggs DF The effects of thalidomide on TNF alpha production from guinea pig alveolar macrophages in vitro and on airways' hyperresponsiveness in vivo. | 0 | 0 |
| 1918 | 19 | 23 | 1356 1997 JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
| 1919 | 0 | 0 | 1358 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):179-179 Nasca MR; OToole EA; Palicharla P; West DP; Woodley DT Thalidomide increases both human keratinocyte proliferation and migration | 0 | 0 |
| 1920 | 0 | 0 | 1359 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):721-721 Hughes MH; Brander TR; Aronson IK; Eilers D; Fiedler BC Thalidomide therapy for discoid and systemic lupus erythematosus. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1921 | 0 | 0 | 1360 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):797-797 Wong J; Brocato D; Kumar R The effect of thalidomide on murine hemangioendothelioma | 0 | 0 |
| 1922 | 0 | 10 | 1361 1997 JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
| 1923 | 0 | 0 | 1364 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
| 1924 | 0 | 0 | 1365 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
| 1925 | 6 | 6 | 1369 1997 M S-MEDECINE SCIENCES 13(4):595-596 Audit CO; Aimar C Thalidomide-induced teratogenesis. | 0 | 0 |
| 1926 | 0 | 0 | 1374 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
| 1927 | 0 | 0 | 1375 1997 NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
| 1928 | 0 | 0 | 1377 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
| 1929 | 4 | 29 | 1379 1997 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
| 1930 | 0 | 1 | 1382 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1087-1087 Jacobson JM; Greenspan JS; Spritzler J Thalidomide for aphthous ulcers in HIV infection - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1931 | 1 | 1 | 1386 1997 SCIENTIST 11(3):8-8 Brown KS Researchers explore thalidomide's therapeutic potential | 0 | 0 |
| 1932 | 0 | 0 | 1387 1997 SEARCH 28(8):239-239 [Anon] Inheriting thalidomide deformities | 0 | 0 |
| 1933 | 0 | 0 | 1391 1998 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 216:U267-U267 Swartz GM; Shah JH; Fogler WE; Papathanassiu A; Madsen JW; Green SJ 2-methyl-2-phthalimidino-glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastases. | 0 | 0 |
| 1934 | 2 | 8 | 1392 1998 AIDS 12(3):334-335 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys | 0 | 0 |
| 1935 | 0 | 0 | 1393 1998 AIDS PATIENT CARE AND STDS 12(3):231-231 [Anon] Thalidomide studied in asymptomatic patients | 0 | 0 |
| 1936 | 0 | 0 | 1402 1998 ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
| 1937 | 0 | 0 | 1403 1998 ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
| 1938 | 0 | 0 | 1410 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
| 1939 | 0 | 0 | 1411 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
| 1940 | 0 | 0 | 1412 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1941 | 0 | 0 | 1413 1998 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
| 1942 | 0 | 0 | 1414 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
| 1943 | 0 | 0 | 1415 1998 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
| 1944 | 0 | 0 | 1416 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
| 1945 | 5 | 7 | 1418 1998 BONE MARROW TRANSPLANTATION 22(9):933-934 Sastry PSRK; Powles RL Thalidomide for chronic GVHD | 0 | 0 |
| 1946 | 1 | 1 | 1419 1998 BONE MARROW TRANSPLANTATION 22(9):934-934 Kami M; Ogawa S; Mitani K; Hirai H Thalidomide for chronic GVHD - Reply | 0 | 0 |
| 1947 | 0 | 0 | 1425 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| 1948 | 0 | 0 | 1432 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| 1949 | 0 | 0 | 1434 1998 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
| 1950 | 0 | 0 | 1435 1998 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1951 | 0 | 0 | 1436 1998 GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
| 1952 | 0 | 0 | 1438 1998 HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
| 1953 | 0 | 0 | 1447 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
| 1954 | 0 | 0 | 1448 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
| 1955 | 0 | 0 | 1456 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
| 1956 | 2 | 5 | 1458 1998 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
| 1957 | 1 | 5 | 1459 1998 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
| 1958 | 0 | 0 | 1460 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
| 1959 | 0 | 0 | 1466 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
| 1960 | 0 | 0 | 1468 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1961 | 0 | 0 | 1469 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
| 1962 | 0 | 0 | 1470 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
| 1963 | 0 | 0 | 1471 1998 NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
| 1964 | 0 | 0 | 1472 1998 NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
| 1965 | 0 | 0 | 1479 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
| 1966 | 0 | 0 | 1480 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
| 1967 | 1 | 1 | 1483 1999 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 56(17):1721-1725 Keravich DP; Daniels CE Challenges of thalidomide distribution in a hospital setting | 0 | 0 |
| 1968 | 0 | 0 | 1485 1999 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 159(3):A271-A271 Lindsay L; Oliver S; Freeman S; Regis J; Krauss A; Kaplan G The role of thalidomide and steroid in modulating the expression of TNF-alpha (TNA-a) and IL-6 in the hyperoxic newborn rat lung. | 0 | 0 |
| 1969 | 0 | 0 | 1491 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| 1970 | 0 | 0 | 1493 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1971 | 0 | 0 | 1496 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 1972 | 0 | 0 | 1499 1999 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
| 1973 | 0 | 0 | 1500 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 1974 | 0 | 0 | 1501 1999 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
| 1975 | 0 | 0 | 1502 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| 1976 | 0 | 0 | 1503 1999 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
| 1977 | 0 | 0 | 1504 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 1978 | 0 | 0 | 1505 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 1979 | 0 | 0 | 1506 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| 1980 | 0 | 0 | 1507 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1981 | 0 | 0 | 1508 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 1982 | 0 | 0 | 1509 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
| 1983 | 0 | 0 | 1510 1999 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
| 1984 | 0 | 0 | 1511 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 1985 | 0 | 0 | 1512 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 1986 | 0 | 0 | 1513 1999 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
| 1987 | 0 | 0 | 1514 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| 1988 | 0 | 0 | 1515 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 1989 | 0 | 0 | 1516 1999 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
| 1990 | 0 | 0 | 1517 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1991 | 0 | 0 | 1518 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
| 1992 | 0 | 0 | 1519 1999 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
| 1993 | 0 | 0 | 1520 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 1994 | 11 | 51 | 1524 1999 CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 5 |
| 1995 | 0 | 1 | 1531 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 1996 | 20 | 36 | 1538 1999 ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
| 1997 | 0 | 0 | 1555 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| 1998 | 0 | 0 | 1556 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
| 1999 | 0 | 0 | 1558 1999 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
| 2000 | 12 | 52 | 1559 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2001 | 7 | 32 | 1568 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 2002 | 6 | 23 | 1572 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 2003 | 1 | 1 | 1575 1999 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
| 2004 | 0 | 0 | 1580 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 2005 | 2 | 12 | 1583 1999 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
| 2006 | 0 | 0 | 1587 1999 NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
| 2007 | 0 | 0 | 1590 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
| 2008 | 0 | 0 | 1593 1999 PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
| 2009 | 11 | 13 | 1594 1999 PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
| 2010 | 11 | 30 | 1601 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2011 | 0 | 0 | 1605 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
| 2012 | 0 | 0 | 1606 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
| 2013 | 0 | 0 | 1612 2000 AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
| 2014 | 0 | 0 | 1618 2000 ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
| 2015 | 0 | 0 | 1619 2000 ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
| 2016 | 0 | 0 | 1620 2000 ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
| 2017 | 0 | 0 | 1621 2000 ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
| 2018 | 0 | 0 | 1627 2000 ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
| 2019 | 83 | 113 | 1630 2000 BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
| 2020 | 0 | 0 | 1633 2000 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2021 | 0 | 0 | 1634 2000 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
| 2022 | 0 | 0 | 1635 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
| 2023 | 0 | 0 | 1636 2000 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
| 2024 | 0 | 0 | 1637 2000 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
| 2025 | 0 | 0 | 1638 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
| 2026 | 0 | 0 | 1639 2000 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
| 2027 | 0 | 0 | 1640 2000 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
| 2028 | 0 | 0 | 1641 2000 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
| 2029 | 0 | 0 | 1642 2000 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
| 2030 | 0 | 0 | 1643 2000 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2031 | 0 | 0 | 1644 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 2032 | 0 | 0 | 1645 2000 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
| 2033 | 0 | 0 | 1646 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
| 2034 | 0 | 0 | 1647 2000 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
| 2035 | 0 | 0 | 1648 2000 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
| 2036 | 0 | 0 | 1649 2000 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
| 2037 | 0 | 0 | 1650 2000 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
| 2038 | 0 | 0 | 1651 2000 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
| 2039 | 0 | 0 | 1652 2000 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
| 2040 | 0 | 0 | 1653 2000 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2041 | 0 | 0 | 1654 2000 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
| 2042 | 0 | 0 | 1655 2000 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
| 2043 | 0 | 0 | 1656 2000 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
| 2044 | 0 | 0 | 1657 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| 2045 | 0 | 0 | 1658 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
| 2046 | 0 | 0 | 1659 2000 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
| 2047 | 0 | 0 | 1660 2000 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
| 2048 | 0 | 0 | 1661 2000 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
| 2049 | 0 | 0 | 1662 2000 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
| 2050 | 0 | 0 | 1663 2000 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2051 | 0 | 0 | 1664 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
| 2052 | 0 | 0 | 1665 2000 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
| 2053 | 0 | 0 | 1666 2000 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
| 2054 | 0 | 0 | 1667 2000 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
| 2055 | 0 | 0 | 1668 2000 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
| 2056 | 0 | 0 | 1669 2000 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
| 2057 | 0 | 0 | 1670 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
| 2058 | 0 | 0 | 1671 2000 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
| 2059 | 0 | 0 | 1672 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| 2060 | 0 | 0 | 1673 2000 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2061 | 0 | 0 | 1674 2000 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
| 2062 | 0 | 0 | 1675 2000 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
| 2063 | 0 | 0 | 1676 2000 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
| 2064 | 0 | 0 | 1682 2000 BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 2065 | 0 | 0 | 1687 2000 CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 2066 | 6 | 16 | 1689 2000 CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 2067 | 0 | 0 | 1691 2000 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
| 2068 | 5 | 15 | 1692 2000 CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
| 2069 | 0 | 0 | 1695 2000 CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
| 2070 | 0 | 0 | 1698 2000 CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2071 | 0 | 0 | 1699 2000 CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 2072 | 53 | 221 | 1700 2000 CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
| 2073 | 0 | 0 | 1702 2000 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| 2074 | 0 | 0 | 1703 2000 DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
| 2075 | 0 | 0 | 1704 2000 DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
| 2076 | 0 | 0 | 1710 2000 EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
| 2077 | 0 | 0 | 1712 2000 EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
| 2078 | 0 | 0 | 1713 2000 EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
| 2079 | 0 | 0 | 1714 2000 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 2080 | 0 | 0 | 1715 2000 GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2081 | 0 | 0 | 1717 2000 GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
| 2082 | 0 | 0 | 1719 2000 GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| 2083 | 2 | 2 | 1720 2000 GUT 47(1):156-156 Ryan J Thalidomide treatment of oesophageal ulceration | 0 | 0 |
| 2084 | 0 | 0 | 1722 2000 HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| 2085 | 22 | 40 | 1723 2000 HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
| 2086 | 0 | 0 | 1729 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
| 2087 | 0 | 0 | 1730 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
| 2088 | 0 | 0 | 1731 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
| 2089 | 0 | 0 | 1732 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
| 2090 | 1 | 1 | 1744 2000 JOURNAL OF INFECTIOUS DISEASES 181(4):1521-1521 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (vol 181, pg 954, 2000) | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2091 | 4 | 5 | 1747 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):640-640 Kaplan G Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection - Reply | 0 | 0 |
| 2092 | 0 | 0 | 1752 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 2093 | 0 | 0 | 1755 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| 2094 | 0 | 0 | 1761 2000 MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
| 2095 | 0 | 0 | 1762 2000 MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
| 2096 | 0 | 0 | 1765 2000 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
| 2097 | 1 | 4 | 1768 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-976 Barlogie B Thalidomide in multiple myeloma - Reply | 0 | 0 |
| 2098 | 0 | 0 | 1770 2000 ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
| 2099 | 0 | 0 | 1771 2000 ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
| 2100 | 0 | 0 | 1772 2000 ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
Page 7: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22